Guillain-Barre syndrome induced by pembrolizumab and sunitinib: A case report

被引：10

作者：

Han, Chen ^{[1
]}

Ma, Jin-An ^{[1
]}

Zhang, Ying ^{[1
]}

Jiang, Yuna ^{[1
]}

Hu, Chunhong ^{[1
]}

Wu, Yuanqiang ^{[1
]}

机构：

[1] Cent South Univ, Dept Oncol, Xiangya Hosp 2, 139 Renmin Rd, Changsha 410011, Hunan, Peoples R China

来源：

MOLECULAR AND CLINICAL ONCOLOGY | 2020年 / 13卷 / 01期

关键词：

Guillain-Barre syndrome; pembrolizumab; immune-checkpoint inhibitor; sunitinib; renal cell carcinoma; intravenous immunoglobulin; REGULATORY T-CELLS; IPILIMUMAB; CARCINOMA; NIVOLUMAB;

D O I：

10.3892/mco.2020.2042

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pembrolizumab, an immune checkpoint inhibitor against the programmed death-1 pathway, has been used in combination with acitinib for the first-line treatment of advanced renal cell carcinoma. Neurotoxicity is a rare immune-related adverse event (irAE). The present study reports a case of Guillain-Barre syndrome (GBS) induced by pembrolizumab and sunitinib, and reviews other previous studies to elucidate the clinical characteristics and suitable management of this rare irAE. An advanced renal cell carcinoma patient who received several cycles of pembrolizumab combined with sunitinib developed limb weakness and numbness of the extremities, and was diagnosed with GBS by electrodiagnostic and cerebrospinal fluid examination. The patient improved after treatment with intravenous immunoglobulin along with prednisone. To the best of our knowledge, this is the first case of GBS during treatment with pembrolizumab in combination with sunitinib in advanced renal cell carcinoma.

引用

页码：38 / 42

页数：5

共 33 条

[1] New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects [J].

Aparicio-Gallego, Guadalupe ;

Blanco, Moises ;

Figueroa, Angelica ;

Garcia-Campelo, Rosario ;

Valladares-Ayerbes, Manuel ;

Grande-Pulido, Enrique ;

Anton-Aparicio, Luis .

MOLECULAR CANCER THERAPEUTICS, 2011, 10 (12) :2215-2223

[2] Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology [J].

Barbee, Meagan S. ;

Ogunniyi, Adebayo ;

Horvat, Troy Z. ;

Dang, Thu-Oanh .

ANNALS OF PHARMACOTHERAPY, 2015, 49 (08) :907-937

[3] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[4] Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy [J].

de Maleissye, Marie-Florence ;

Nicolas, Guillaume ;

Saiag, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (03) :296-297

[5] Regulatory T Cells in Melanoma Revisited by a Computational Clustering of FOXP3+ T Cell Subpopulations [J].

Fujii, Hiroko ;

Josse, Julie ;

Tanioka, Miki ;

Miyachi, Yoshiki ;

Husson, Francois ;

Ono, Masahiro .

JOURNAL OF IMMUNOLOGY, 2016, 196 (06) :2885-2892

[6] Acute demyelinating polyneuropathy induced by nivolumab [J].

Fukumoto, Yuta ;

Kuwahara, Motoi ;

Kawai, Shigeru ;

Nakahama, Kenji ;

Kusunoki, Susumu .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (04) :435-+

[7] Immune mediated neuropathy following checkpoint immunotherapy [J].

Gu, Yufan ;

Menzies, Alexander M. ;

Long, Georgina V. ;

Fernando, S. L. ;

Herkes, G. .

JOURNAL OF CLINICAL NEUROSCIENCE, 2017, 45 :14-17

[8] Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Haanen, J. B. A. G. ;

Carbonnel, F. ;

Robert, C. ;

Kerr, K. M. ;

Peters, S. ;

Larkin, J. ;

Jordan, K. .

ANNALS OF ONCOLOGY, 2017, 28 :119-142

[9] Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma [J].

Hansen, Caroline Randrup ;

Grimm, Daniela ;

Bauer, Johann ;

Wehland, Markus ;

Magnusson, Nils E. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (02)

[10] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

← 1 2 3 4 →